CAJ | 학술논문

目的：观察地西他滨联合C A G方案应用于骨髓增生异常综合征治疗的临床效果。方法选取2007年2月至2012年1月诊治的骨髓增生异常综合征患者共73例，分为治疗组（37例）和对照组（36例），对照组实施CAG方案治疗，治疗组患者实施CAG方案与地西他滨联合治疗。比较两组患者治疗前后血管内皮生长因子变化，治疗有效率，生存时间及不良反应。结果治疗后1、3、7、14 d ，两组患者的血管内皮生长因子水平均明显低于治疗前（P＜0．05），且治疗组较对照组降低更明显，差异均有统计学意义（P＜0．05）；治疗组和对照组的治疗总有效率分别为75．6％和61．1％，治疗组高于对照组，差异有统计学意义（ P＜0．05）；两组总体生存时间和无病生存时间对比，治疗组均明显优于对照组，差异有统计学意义（ P＜0．05）；治疗组的不良反应发生率（67．2％）明显优于对照组（77．8％），差异有统计学意义（P＜0．05）。结论地西他滨与CAG方案联合治疗骨髓增生异常综合征，患者生存时间长，效果明显，值得应用。
목적：관찰지서타빈연합C A G방안응용우골수증생이상종합정치료적림상효과。방법선취2007년2월지2012년1월진치적골수증생이상종합정환자공73례，분위치료조（37례）화대조조（36례），대조조실시CAG방안치료，치료조환자실시CAG방안여지서타빈연합치료。비교량조환자치료전후혈관내피생장인자변화，치료유효솔，생존시간급불량반응。결과치료후1、3、7、14 d ，량조환자적혈관내피생장인자수평균명현저우치료전（P＜0．05），차치료조교대조조강저경명현，차이균유통계학의의（P＜0．05）；치료조화대조조적치료총유효솔분별위75．6％화61．1％，치료조고우대조조，차이유통계학의의（ P＜0．05）；량조총체생존시간화무병생존시간대비，치료조균명현우우대조조，차이유통계학의의（ P＜0．05）；치료조적불량반응발생솔（67．2％）명현우우대조조（77．8％），차이유통계학의의（P＜0．05）。결론지서타빈여CAG방안연합치료골수증생이상종합정，환자생존시간장，효과명현，치득응용。
Objective To observe the clinical effect of decitabine combined with CAG scheme in the treatment of myelodysplastic syndrome .Methods 73 cases of myelodysplastic syndrome in our hospital from February 2007 to January 2012 were chosen and randomly divided into the control group(36 cases) and the treatment group(37 cases) . The control group was treated with the CAG regimen ,while the treatment group was given the CAG scheme com‐bined with decitabine treatment .The changes of vascular endothelial growth factor(VEGF) before treatment and after treatment ,total effective rate ,survival time and adverse reactions were compared between the two groups .Results The VEGF levels on 1 ,3 ,7 ,14 d after treatment in the two group were all significantly lower than those before thera‐py(P<0 .05) ,moreover the decrease in the treatment group was more significant than the control group ,the differ‐ence was statistically significant(P<0 .05);the total effective rates of the treatment group and the control group were 75 .6% and 61 .1% respectively ,the treatment group was higher than the control group with statistical difference(P<0 .05);the overall survival time and disease‐free survival time in the treatment group were significantly better than those in the control group ,the differences were statistically significant(P<0 .05);the incidence rate of adverse reac‐tions in the treatment group was 67 .2% ,which was significantly lower than 77 .8% in the control group ,the differ‐ences were statistically significant(P<0 .05) .Conclusion Decitabine combined with CAG scheme in treating myelo‐dysplastic syndrome has long survival time ,obvious effect and is worthy of promotion .